FDA reviews psychiatric side effects of Chantix
By Associated Press

The Food and Drug Administration announced Friday it will convene a public meeting in October to review the risks of psychiatric and behavioral side effects with Pfizer's anti-smoking drug Chantix.

The agency says in a federal notice it will convene its panel of psychiatric drug experts to discuss the pill's risks and how to manage them.

Since 2009 Chantix has carried the government's strongest safety warning due to links to hostility, agitation, depression and suicidal thoughts. The warning was added after the FDA received dozens of reports of suicide and suicidal behavior among patients taking Chantix.

At that time the FDA also required Pfizer to conduct additional studies.

A spokeswoman for Pfizer said Friday that the company recently submitted new data to the FDA designed to show the drug's safety.

Copyright © Sep 23, 2014, WDEL/Delmarva Broadcasting Company. All Rights Reserved.
This material may not be published, broadcast, rewritten, or redistributed.

WDEL News Tools:
Printer friendly version
Back to homepage

 Latest News

 Follow Us

Facebook Twitter
RSS Mobile
Email Updates

Copyright © 2014, Delmarva Broadcasting Company. All Rights Reserved.   Terms of Use.
WDEL Statement of Equal Employment Opportunity and Outreach